News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
